Alteration of the gut microbiota and metabolite phenylacetylglutamine in patients with severe chronic heart failure
Chronic Heart Failure (CHF) is the end result of nearly all cardiovascular disease and is the leading cause of deaths worldwide. Studies have demonstrated that intestinal flora has a close relationship with the development of Cardiovascular Disease (CVD) and plays a vital role in the disease evoluti...
Main Authors: | Zhendong Zhang, Bin Cai, Yanzhuan Sun, Haiyan Deng, Hongwei Wang, Zengyong Qiao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-01-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.1076806/full |
Similar Items
-
Study on the Changes of Intestinal Flora and Its Metabolite Phenylacetylglutamine in Patients with Chronic Heart Failure
by: ZHANG Zhendong, CAI Bin, WANG Hongwei, QIAO Zengyong
Published: (2023-10-01) -
Dysbiosis of Gut Microbiota and Metabolite Phenylacetylglutamine in Coronary Artery Disease Patients With Stent Stenosis
by: Chen Fang, et al.
Published: (2022-03-01) -
Prognostic value of plasma phenylalanine and gut microbiota-derived metabolite phenylacetylglutamine in coronary in-stent restenosis
by: Yuan Fu, et al.
Published: (2022-08-01) -
Phenylacetylglutamine, a Novel Biomarker in Acute Ischemic Stroke
by: Fang Yu, et al.
Published: (2021-12-01) -
Phenylacetylglutamine as a risk factor and prognostic indicator of heart failure
by: Xiao Zong, et al.
Published: (2022-08-01)